Biogen

A biotechnology company focused on neurological diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

• New lupus drug shows promise in major trial Results expected Sep 2026 (estimated)
• New lupus drug shows promise in major trial Results expected Sep 2026 (estimated)
• New hope for lupus skin lesions: drug trial targets stubborn cases Results expected Oct 2026 (estimated)
• MS drug shot study tracks immune reactions Results expected Oct 2026 (estimated)
• New drug could save transplanted kidneys from rejection Results expected Dec 2026 (estimated)